Introduction {#sec1-1}
============

According to Ayurvedic classics, *Agni* is responsible for *Ayu* (age), *Varna* (colour), *Bala* (power), *Swasthya* (health), *Utsaha* (excitement), *Upachaya* (digestion), *Prabha*, *Oja* and *Teja*\[[@ref1]\] and *Agni* takes a pivot role in the etiopathogenesis of all human ailments.\[[@ref2][@ref3]\] According to *Acharya Charaka*, indulging in *Ajirna*, *Atibhojana* (over eating), *Vishama Bhojana* (irregular diet), *Asatmya* (incompatible diet) and *Sandushta Bhojana* produces *Shuktata* due to *Agni Dushti* (impairment of *Agni*) followed by *Ama* and *Amavisha* which further develops *Ajirna* (indigestion) by vitiating *Dosha*.\[[@ref4]\] Continuous indulgence in improper diet and erratic lifestyle basically aggravates *Pitta Dosha* which leads the disease into acute condition of *Vidagdhajirna* (indigestion) which due to ignorance inturn converts into *Amlapitta* in long run.

It is better to consider *Amlapitta* as a syndrome (acid reflux syndrome)\[[@ref5]\] rather than a particular gastrointestinal disease due to the same causative factors with similar signs and symptoms as in Ayurvedic parlance closely resembles with gastritis,\[[@ref6]\] non-ulcer dyspepsia,\[[@ref7]\] hyperchlorhydria,\[[@ref8]\] as well as hypochlorhydria\[[@ref9]\] and in chronic stage, it may lead to gastric ulcer. Gastrointestinal disorders become lifestyle maladies when people shift their eating pattern toward ready-to-eat commercial junk meals from homemade food and adopt erratic lifestyles. According to the National Digestive Diseases Information Clearinghouse, the prevalence rate of gastritis in India is 10,572,391 and that of peptic ulcer is 5 million (1987).\[[@ref10]\]

Knowledge of etiological factors, responsible for genesis of a particular disease, is essential in the selection of appropriate therapies which are opposite to disease as well as etiological factors (*Vyadhi-Hetu Pratidwandwi*) because the attributes of *Dosha* resembles the etiological factors which vitiate the *Dosha*.

Various types of *Avarana* (layer) should be considered into the pathogenesis. *Avarana* is mainly of three types, viz., 1. *Sama-Vata Avrita* by *Vriddha-Pitta* and *Kapha*, 2. *Vriddha-Vata Avrita* by *Sama-Pitta* and *Kapha*, 3. *Vriddha-Vata Avrita* by *Vriddha-Pitta* and *Kapha*. In the disease *Amlapitta*, third pathogenesis is rare. Hence, the first two are commonly considered in which clinical conditions such as *Kapholvana* and *Pittolvana* type of *Amlapitta* have been found.

Increased *Drava* and *Amla Guna* of *Pachaka Pitta* plays an important role in the pathogenesis of *Amlapitta*. *Sneha* is one of the special qualities of both *Kapha* and *Pitta*, but *Sneha* is present in *Pitta* in feeble quantity. *Dravya* which have the property of *Kleda* are *Snigdha*. *Sneha* performs the function of *Mardava* (softens the food stuff). Hence, it can be declared that *Sneha* is the common property of *Kledaka Kapha* and *Pachaka Pitta*. Hence, both of them are responsible for the pathogenesis of *Amlapitta* which is a *Pathya Asadhya*, *Bheshaj Asadhya* and *Kashtasadhya Vyadhi*. Hence, *Nidana Parivarjana*, *Hetu Viparita*, *Vyadhi* and *Dosha Pratyanika* (*Kapha-Pittahara*) therapies would be beneficial in *Amlapitta* \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\].

Aims and objectives {#sec2-1}
-------------------

1\. To assess the role of *Doshik* predominance in the management of *Amlapitta*.

Materials and Methods {#sec1-2}
=====================

This clinical study is registered in the Clinical Trial Registry of India, ICMR, New Delhi (CTRI; [www.ctri.nic.in](www.ctri.nic.in)) vide CTRI/2011/09/002003 and explained as per the Consolidated Standards of Reporting Trials statement 2010.\[[@ref11]\] A total of 112 clinically diagnosed patients of *Amlapitta* attending outpatient and inpatient department of PG Hospital, Kayachikitsa at IPGT and RA, Gujarat Ayurved University, Jamnagar, were registered for this study. Out of 112, five patients were dropped out for several reasons.

Criteria for diagnosis {#sec2-2}
----------------------

### Subjective criteria {#sec3-1}

A total of 112 patients were diagnosed and confirmed by the presence of *Pratyatma Niyata Lakshana* (cardinal features)\[[@ref12]\] of *Amlapitta* (*Avipaka* \[indigestion\], *Klama* \[exhaustion\], *Utklesha* \[nausea\], *Tikta-Amla Udgara* \[eructation with bitter and sour taste\], *Gaurava* \[feeling of heaviness of the body\], *Hrit-Kantha-Daha* \[burning sensation in the chest and throat\], and *Aruchi* \[loss of appetite\]) in general.

Patients of *Kaphaja Amlapitta* will be diagnosed by the presence of the symptoms\[[@ref13][@ref14]\] such as *Aruchi*, *Gaurava*, *Jadyata*, *Kaphanisthivana* (expectoration of thick phlegm), *Lepa* (coating of tongue), *Sada* (Lassitude), *Sheeta* (coldness), *Vami* (vomiting) and *Kandu* (itching sensation) whereas *Pittaja Amlapitta* will be diagnosed by the presence of the symptoms\[[@ref14][@ref15]\] such as *Nanavidha Pravritti* (fluids eliminated through rectum with different colors), *Trishna* (excessive thirst), *Hrit-Kantha-Kukshi Daha* (burning sensation in chest, throat, and abdomen), *Murccha* (fainting), *Bhrama* (giddiness), *Moha* (delusion), *Anala Sada* (poor digestive power), *Hrillasa* (nausea), *Sweda* (excessive sweating) and *Anga Peetata* (yellowish discoloration of the skin).

Objective criteria {#sec2-3}
------------------

Out of 112, five patients were dropped out for several reasons. The objective criteria were taken; however, to exclude other pathological conditions, the following investigations were carried out (a) blood: total leukocyte count (TLC), differential leukocyte count (DLC), hemoglobin percentage (HB%), erythrocyte sedimentation rate (ESR), fasting blood sugar (FBS), liver function tests (LFT), lipid profile (b) stool: routine microscopic examination of the stool and (c) urine: routine examination.

Criteria for selection of patients {#sec2-4}
----------------------------------

### Inclusion criteria {#sec3-2}

\(1\) Age: Patients between 21 and 60 years of age. (2) Sex: Patients of both sex. (3) Presence of cardinal features of *Amlapitta* as well as typical features of *Kapha* and *Pitta Dosha*-predominant *Amlapitta*. (4) Patients not taking any other medicines for *Amlapitta*. (5) Chronicity of \>3 months.

### Exclusion criteria {#sec3-3}

\(1\) Patients with peptic ulcer, duodenal ulcer, carcinoma stomach, cardiac disorders. (2) Taking medicines for any other diseases such as hypertension, diabetes mellitus, ischemic heart diseases and chronic renal failure.

Plan of study {#sec2-5}
-------------

Clinically diagnosed 34 cases of *Kapha* predominant *Amlapitta* were allocated in Group A and 39 patients of *Pitta* predominant *Amlapitta* were allocated in Group B whereas 39 patients were allocated in Group C irrespective of their *Doshik* predominance. *Shunthikhanda* granules was administered to the patients of Group A, *Vasakhanda Kushmandaka* granules were given to the patients of Group B and one of these two drugs was administered randomly to the patients of Group C.

Further, the patients who were randomly treated with *Shunthikhanda* granules, allocated in Group C-1 and the patients who were randomly treated with *Vasakhanda Kushmandaka* granules were allocated in Group C-2 to observe the comparative effectiveness of drugs in between the groups where patients were treated according to *Doshik* predominance and without *Doshik* predominance, respectively. All patients of three groups were administered their recommended drug in a dose of 5 g, orally, twice a day, in between food with water for a period of 30 days. Computer-generated randomization\[[@ref16]\] from [www.randomization.com](www.randomization.com) vide seed 18,135 created on Tuesday; January 03, 2012, at 2:12:18 PM was used for the clinical study.

Criteria for assessment {#sec2-6}
-----------------------

In this study, an effort has been made to follow the guidelines laid down by *Acharya Charaka* for the assessment of results. Having close acquaintance with the various states of the disease, such therapies should be prescribed which may help attainment of the four-fold blessings (*Chatuhshreya*).\[[@ref17]\] *Amlapitta* symptoms rating scale (ASRS) was adopted to assess the relief in each symptom in *Amlapitta* patients. The ASRS is 20 items based on *Rogabala*, *Agnibala*, *Dehabala*, and *Chetasabala*; a disease-specific instrument used to evaluate symptoms of *Amlapitta*. The items are measured on a 5-point Likert-type scale\[[@ref18]\] ranging from 0 = "no discomfort" to 4 = "very severe discomfort." The ASRS was administered at baseline and after the end of 30 days' clinical trial.

Total 100 scores were divided into *Rogabala*, *Dehabala*, *Agnibala* and *Chetasabala*. Thirty-five scores allotted for "*Rogabala*" were subdivided into seven items such as *Hrit-Kantha-Daha*, *Tiktamlodgara*, *Vami*, *Gaurava*, *Utklesha*, *Shula* and *Brahma* for the assessment of the severity of symptoms of *Amlapitta*. Twenty-five scores allotted for "*Agnibala*" were subdivided into five items such as *Abhyavaharana Shakti* (capacity of ingestion of food), *Jarana Shakti* (power of digestion), *Avipaka* and *Aruchi* for the assessment of power of digestion in *Amlapitta*. Twenty scores allotted for "*Dehabala*" were distributed into four items, viz., *Balavriddhi* (strength), *Klama*, *Swara-Varna Yoga* (clarity in voice and luster) and *Sharira Upachaya* (weight gain) for the assessment of bodily strength in *Amlapitta*. Twenty scores allotted for "*Chetasabala*" were subdivided into four items such as *Nidra Labho Yathakalam* (regularity in sleep), "*Sukhena Cha Pratibodhanam"* (feeling of well-being), "*Vaikarikanam Cha Swapnana Darshanam*"(uncomfortable dreams) and "*Mano Buddhi Indriya Avyapatti"* for the assessment of strength of mental faculties in *Amlapitta*.

Statistical analysis {#sec2-7}
--------------------

The data obtained on the basis of observations were subjected to statistical analysis by applying Sigmastat 3.5 software (Software is now based in San Jose, California) in terms of mean, percentage, standard deviation, and standard error. The *t*-test and *P* values were calculated by using paired *t*-test and unpaired *t*-test considered at the level of *P* ≥ 0.05 (insignificant), *P* ≥ 0.002 to ≤ 0.04 (significant), and *P* ≤ 0.001 (highly significant).

Assessment of overall effect of therapy {#sec2-8}
---------------------------------------

For the overall assessment of the therapy, following five categories were taken into consideration:

Complete remission- 100% relief in the clinical signs and symptomsMarked improvement- 76%--99% relief in the clinical signs and symptomsModerate improvement- 51%--75% relief in the clinical signs and symptomsMild improvement- 26--50% relief in the clinical signs and symptomsUnchanged- Below 25% relief in the clinical signs and symptoms.

Follow-up study {#sec2-9}
---------------

After completion of due course of treatment, all the patients were requested to report for follow-up study for 1 week. During this period, no medicine was provided to the patients and recurrence of any symptoms regarding *Rogabala*, *Dehabala*, *Agnibala* and *Chetasabala* as well as impact of therapies on quality of life were observed.

Observations {#sec2-10}
------------

Epidemiological data observed among 112 patients of *Amlapitta* was exhibited in [Graph 1](#F1){ref-type="fig"}. However, features of *Pitta Prakriti* were observed in 51 (45.54%) patients, *Kapha Prakriti* was observed in 33 (29.46%) patients and *Vata Prakriti* was in 28 (25%) patients. Different types of dietary habits such as *Viruddhashana* (intake of contraditory food combination), *Atiguru Bhojana* (excessive heavy diet), *Atiruksha Bhojana* (excessive ununctous diet), *Vidahi Bhojana* (spicy food), intake of *Katu Rasa* and *Lavana Rasa* dominant diet, *Bhuktamatrasya Swapna* (going to sleep just after lunch and dinner), *Atidaryta* (intake diet hurriedly) and *Ativilambita Bhojana* (intake of in a diet very slowl pattern) were observed among 112 patients of *Amlapitta* \[[Graph 2](#F2){ref-type="fig"}\].

![Observed data collected from 112 patients of *Amlapitta*](AYU-38-15-g001){#F1}

![Dietary habits of 112 patients of *Amlapitta*](AYU-38-15-g002){#F2}

26.79% of patients were not doing exercise at all, 52.68% were habituated of *Vegavidharana* (suppression of their natural urges) and 40.18% had the habit of *Prajagarana* (night vigilance). Maximum patients were addicted with tea (97.32%) followed by tobacco (51.79%) observed in this study.

Most of patients were afflicted with *Krodha* (anger -- 54.46%) followed by *Avasada* (depression -- 35.71%), *Chinta* (tension -- 31.25%), and *Lobha* (greedy -- 21.43%).

In this study, all the patients had the cardinal symptoms such as *Avipaka*, *Tiktamlodgara*, *Hrit*-*daha*, *Kantha*-*daha*, *Utklesha*, *Gaurava*, *Aruchi* and *Klama*. Other signs and symptoms observed were *Adhmana* (flatulence), *Udara shula* (abdominal pain), *Nidralpata* (insomnia), *Vibandha* (constipation), *Atipipasa* (excessive thirst), *Bhrama* (giddiness), *Kampa* (tremor) and *Angasada* (lethargy) \[[Graph 3](#F3){ref-type="fig"}\].

![Cardinal symptoms observed in 112 patients of *Amlapitta*](AYU-38-15-g003){#F3}

Maximum patients had the previous history of *Ajirna* (49.11%) followed by *Amlapitta* (47.32%) and had the chronicity of 3 months to 1 year (45.54%).

*Strotodushti* observed in 112 of patients in this study were *Purishavaha* (100%), *Rasavaha* (72.31%), *Annavaha* (62.89%), *Raktavaha* (39.30%) and *Swedavaha Strotas* (25.50%). Of the total observed 1117 frequency of symptoms of involvement of *Dosha*, majority represented *Kapha* (55.68%) followed by *Pitta* (47.36%) and *Vata* (32.77%).

Effect of therapy {#sec2-11}
-----------------

### Rogabala {#sec3-4}

*Shunthikhanda* granules in Group A and C-1 and *Vasakhanda Kushmandaka* granules in Group B and C-2 provided highly significant relief (*P* \< 0.001) in the symptoms of *Utklesha*, *Tiktamlodgara*, *Gaurava* and *Angasada*, *Hrit-Kantha Daha*, *Chardi* and *Shula*. On *Brahma*, *Shunthikhanda* granules in Group A provided highly significant relief (*P* \< 0.001) and in Group C-1 provided significant relief (*P* \< 0.05) whereas *Vasakhanda Kushmandaka* granules provided significant relief in Group B (*P* = 0.002) and Group C-2 (*P* \< 0.05) \[[Graph 4](#F4){ref-type="fig"}\].

![Effect of therapy on *Rogabala* in Group A, C-1, B and C-2](AYU-38-15-g004){#F4}

### Agnibala {#sec3-5}

*Shunthikhanda* granules in Group A and *Vasakhanda Kushmandaka* granules in Group B provided highly significant relief (*P* \< 0.001) in the symptoms of *Abhyavaharana Shakti*, *Jarana Shakti*, *Aruchi*, *Avipaka* and *Vata-Mutra-Retasam Mukti*. *Shunthikhanda* granules in Group C-1 and *Vasakhanda Kushmandaka* granules in Group C-2 provided highly significant relief (*P* \< 0.001) in the symptoms of *Abhyavaharana Shakti*, *Jarana Shakti*, *Aruchi* and *Avipaka* but insignificant relief (*P* \> 0.05) in *Vata-Mutra-Retasam Mukti* \[[Graph 5](#F5){ref-type="fig"}\].

![Effect of therapy on *Agnibala* in Group A, C-1, B and C-2](AYU-38-15-g005){#F5}

### Dehabala {#sec3-6}

*Shunthikhanda* granules in Group A and *Vasakhanda Kushmandaka* granules in Group B provided highly significant relief (*P* \< 0.001) in the symptoms of *Bala Vriddhi*, *Swara-Varna Yoga*, *Klama* and *Sharira Upachaya*. *Shunthikhanda* granules in Group C-1 and *Vasakhanda Kushmandaka* granules in Group C-2 provided highly significant relief (*P* \< 0.001) in the symptoms of *Balavriddhi*, *Swara-Varna Yoga* and *Klama* and insignificant relief (*P* \> 0.05) in *Sharira Upachaya* \[[Graph 6](#F6){ref-type="fig"}\].

![Effect of therapy on *Dehabala* in Group A, C-1, B and C-2](AYU-38-15-g006){#F6}

### Chetasabala {#sec3-7}

*Shunthikhanda* granules in Group A and *Vasakhanda Kushmandaka* granules in Group B showed highly significant relief (*P* \< 0.001) in the symptoms of *Nidra Labho Yathakalam*, *Sukhena Cha Pratibodhanam*, *Vaikarikanam Cha Swapnana Darshanam* and *Mano Buddhi Indriya Avyapatti*. *Shunthikhanda* granules in Group C-1 showed highly significant relief (*P* \< 0.001) in the symptoms such as *Sukhena Cha Pratibodhanam*, *Vaikarikanam Cha Swapnana Darshanam* and *Mano Buddhi Indriya Avyapatti* and significant relief (*P* \< 0.05) in *Nidra Labho Yathakalam*. *Vasakhanda Kushmandaka* granules in Group C-2 showed statistically highly significant improvement (*P* \< 0.001) in *Sukhena Cha Pratibodhanam*, *Vaikarikanam Cha Swapnana Darshanam*, *Nidra Labho Yathakalam* (*P* = 0.001) and significant relief in *Mano Buddhi Indriya Avyapatti* (*P* \< 0.01) \[[Graph 7](#F7){ref-type="fig"}\].

![Effect of therapy on *Chetasabala* in Group A, C-1, B and C-2](AYU-38-15-g007){#F7}

Comparative effect of therapy {#sec2-12}
-----------------------------

### Rogabala {#sec3-8}

In comparison between Group A and Group C-1 \[[Table 1](#T1){ref-type="table"}\], both showed statistically insignificant improvements with *P* \> 0.05, except in *Gaurava* and *Shula*; therapeutic effect was statistically significant with *P* \< 0.05. In comparison between Group B and Group C-2 \[[Table 2](#T2){ref-type="table"}\], both showed statistically insignificant improvements with *P* \> 0.05. In comparison between Group C-1 and Group C-2 \[[Table 3](#T3){ref-type="table"}\], both showed statistically insignificant improvements with *P* \> 0.05.

###### 

Comparison of the effect of therapy on *Rogabala* between Group A and Group C-1 (unpaired *t*-test)

![](AYU-38-15-g008)

###### 

Comparison of the effect of therapy on *Rogabala* between Group B and Group C-2 (unpaired *t*-test)

![](AYU-38-15-g009)

###### 

Comparison of the effect of therapy on *Dehabala* between Group B and Group C-2 (unpaired *t*-test)

![](AYU-38-15-g010)

### Agnibala {#sec3-9}

In comparison between Group A and Group C-1 \[[Table 4](#T4){ref-type="table"}\], both showed improvements which were statistically highly significant with *P* \< 0.001 in *Abhyavaharana Shakti*, *Jarana Shakti* and *Aruchi*. The effect was statistically insignificant on *Avipaka* and *Vata-Mutra Retasam Mukti* with *P* \> 0.05. In comparison between Group B and Group C-2 \[[Table 5](#T5){ref-type="table"}\], both showed statistically insignificant improvement with *P* \> 0.05.

###### 

Comparison of the effect of therapy on *Agnibala* between Group A and Group C-1 (unpaired *t*-test)

![](AYU-38-15-g011)

###### 

Comparison of the effect of therapy on *Agnibala* between Group B and Group C-2 (unpaired *t*-test)

![](AYU-38-15-g012)

### Dehabala {#sec3-10}

In comparison between Group A and Group C-1 \[[Table 6](#T6){ref-type="table"}\], both showed statistically insignificant improvements in *Swara-Varna Yoga* and *Sharia Upachaya* with *P* \> 0.05, highly significant (*P* \< 0.001) in *Balavriddhi* and statistically significant (*P* \< 0.05) in *Klama*. In comparison between Group B and Group C-2 \[[Table 3](#T3){ref-type="table"}\], both showed statistically insignificant improvements with *P* \> 0.05.

###### 

Comparison of the effect of therapy on *Dehabala* between Group A and Group C-1 (unpaired *t*-test)

![](AYU-38-15-g013)

### Chetasabala {#sec3-11}

Comparative effect of therapy on *Nidra Labho Yathakalam* and *Vaikarikanam Cha Swapnana Darshanam* in between Group A and Group C-1 was statistically insignificant with *P* \> 0.05 \[[Table 7](#T7){ref-type="table"}\] but significant on *Mano Buddhi Indriya Avyapatti* with *P* \< 0.05 and highly significant on *Sukhena Cha Pratibodhanam* (*P* \< 0.001). In comparison between Group B and Group C-2 \[[Table 8](#T8){ref-type="table"}\], both showed statistically insignificant improvements with *P* \> 0.05.

###### 

Comparison of the effect of therapy on *Chetasabala* between Group A and Group C-1 (unpaired *t*-test)

![](AYU-38-15-g014)

###### 

Comparison of the effect of therapy on *Chetasabala* between Group B and Group C-2 (unpaired *t*-test)

![](AYU-38-15-g015)

Comparison of overall effects as well as average relief of therapies {#sec2-13}
--------------------------------------------------------------------

Regarding overall effect of therapy, marked positive improvement in Group A was 35.29%, in Group B, 26.47%, in Group C-1, 23.08% and Group C-2, 16.67%. Moderate improvement in Group A was 52.94%, in Group B, 58.82%, in Group C-1, 42.86% and in C-2, 61.11% whereas mild improvement observed in Group A was 11.76%, in Group B, 14.71%, in Group C-1, 23.81%, and in Group C-2, 11.11%. No improvement was observed only in Group C-1 (4.76%) and C-2 (5.56%). Complete remission (2.56%) was observed only in Group C-2 (5.56%) \[[Table 9](#T9){ref-type="table"}\].

###### 

Overall effect of therapy

![](AYU-38-15-g016)

Average relief of Group A and Group B where *Shunthikhanda* and *Vasakhanda Kushmandaka* granules were given according to *Doshik* predominance was far better (68.78% and 65.4%, respectively) than that of Group C-1 and C-2 (60.40% and 64.46%) where *Shunthikhanda* and *Vasakhanda Kushmandaka* granules were given randomly without any *doshik* predominance \[[Table 10](#T10){ref-type="table"}\].

###### 

Comparison on average relief of the effect of therapy between Group A, Group B, Group C-1, and Group C-2

![](AYU-38-15-g017)

After 1 week of follow-up, lesser incidence of recurrence of disease was reported in Group A (14.71%) and Group B (20.59%) rather than Group C-1 (33.33%) and Group C-2 (22.22%). *Shunthikhanda* granules in Group A exert a more sustained effect than *Vasakhanda Kushmandaka* granules in Group B on patients of *Amlapitta* even after discontinuation of the drug for 1-week follow-up \[[Table 11](#T11){ref-type="table"}\].

###### 

Recurrence of *Amlapitta* during follow-up

![](AYU-38-15-g018)

Discussion {#sec1-3}
==========

Manifestation of a disease depends upon the intensity of conjunction of *Nidana*, *Dosha* and *Dushya*. *Amlapitta* is one of the most prevalent lifestyle disorder caused by *Mandagni* due to vitiation of *Vata* (32.77%), *Pitta* (47.36%) and *Kapha* (55.68%) as well as *Purishavaha* (100%), *Rasavaha* (72.31%), *Annavaha* (62.89%), *Raktavaha* (39.30%) and *Swedavaha* (25.50%) *Strotasa*. *Amashaya* is the seat of *Samana Vayu*, *Pachaka Pitta*, *Kledaka Kapha* and also the root of *Annavaha Strotasa* whereas *Grahani* is the seat of *Agni*. *Samana Vayu*, *Pachaka Pitta* and *Kledaka Kapha* may involve in the *Sthanasamshraya* at *Amashaya* including *Grahani* where simultaneously *Khavaigunya* takes place. When *Vata* gets vitiated by *Ama*, there is the possibility of *Marga Avarana* by *Vriddha Pitta* and *Kapha*. Hence, *Amlapitta* is the disease condition produced by *Pitta-Kapha Avrita Vata*.

A patient constitutes the *Karyadesha* or the site for administration of therapies with a view to bringing about equilibrium of *Dhatu*. Manifestation of disease depends on resemblance of the afflicted *Dosha-Dushya-Prakriti-Desa-Kala-Bala* of individual with that of the *Hetubala* and *Vyadhibala*. The dosage in which a therapy is to be administered depends on the intensity of morbidity as well as the strength of the patients.

Maximum patients (29.46%) were in the age group of 41--50 years (*Pitta*-predominant state). *Pitta Prakriti* (45.54%), afflicted with *Krodha* (54.46%), habituated in taking of *Viruddhashana* (83.04%); *Vidahi* (84.82%), *Katu* (80.36%) and *Lavana Rasa* (53.57%) predominant diet as well as intake of *Guru Ahara* (heavy in quantity and quality -- 96.43%), *Shita Ahara* (32.14%) and habits of *Bhuktamatrasya Swapna* (73.21%) cause *Agninirvapana* by increasing *Dravatva* of *Pachaka Pitta* and *Snigdhata* of *Kledaka Kapha* because basically *Drava* and *Snigdha Guna* procreate *Klinnata* in our body. This excessive *Kleda* causes *Agnimandya* and produces *Ama*. Due to *Shuktapaka*, *Ama* gets vitiated and produces *Amavisha* which again comes in contact with *Vidagdha Pachaka Pitta* which is evolve as *Vidagdhajirna*. If the disease is neglected, establishing their affinity in *Amashaya* and *Grahani*, the vitiated *Doshas* lead the condition into *Amlapitta*.

In *Shamana* therapy, *Kapha-Pittahara Chikitsa* is the principle of treatment for *Amlapitta*. Due to *Kapha*-pacifying ingredients in *Shunthikhanda* granules and *Pitta*-pacifying ingredients in *Vasakhanda Kushmandaka* granules, the drugs were advocated to the patients of *Kapha*-predominant and *Pitta*-predominant *Amlapitta*, respectively \[Figures [1](#F8){ref-type="fig"} and [2](#F9){ref-type="fig"}\].

![Probable mode of action of *Shunthikhanda* granules](AYU-38-15-g019){#F8}

![Probable mode of action of *Vasakhanda Kushmandaka* granules](AYU-38-15-g020){#F9}

Average relief of the patients (in Group A and B) whom medicines were given according to *Doshik* predominance was far better (68.78% and 65.4%) than the patients (in Group C-1 and C-2) where medicines were given randomly without any *doshik* predominance (60.40% and 64.46%, respectively).

The *Phalashruti* is that the vitiated *Dosha*, alleviated by *Langhana* and *Pachana*, may be aggravated at any time, but those who are eliminated by proper *Samshodhana* therapies do not recur further.\[[@ref19]\] However, in this study, we knowingly had to ignore *Aptopadesha* to compromise on patients' preference and it was reflected on recurrence of the disease which was observed more in the patients of Group C-1 (33.33%) and C-2 (22.22%) than of Group A (14.71%) and Group B (20.59%).

Conclusion {#sec1-4}
==========

In the era of rapid civilization, *Amlapitta* evolves as the most developing lifestyle disorder where *Pitta* and *Kapha* take pivot role associated with *Vata* in etiopathogenesis of *Amlapitta*. *Amlapitta* adversely affects the quality of life of patients, making it difficult to make dietary choices and causing sleep loss even hampering social life and contributes to a higher medical cost. The long-term effects can also lead to poorer quality of life. Diagnosis of the disease and treatment (*Dosha-Dushya Vighatana*) on the basis of *Doshik* predominance proved beneficial in this study.
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